SpineTop Stories

Alphatec Announces Commercial Launch of ALIF IdentiTi™ Porous Titanium Interbody System Implant

CARLSBAD, Calif., July 18, 2019 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today the commercial release of its IdentiTi Large Window Porous Titanium Interbody Implant System for anterior lumbar interbody fusion (ALIF) procedures.

ALIF IdentiTi-LW Porous Titanium Interbody Implant

“The spine market’s new organic innovation machine continues to deliver meaningful clinical distinction,” said Pat Miles, Chairman and Chief Executive Officer.  “With this fifth of twelve new product releases expected for 2019, ATEC is on track to fulfill its aggressive new product development and commercialization program. The innovation we are introducing is increasingly being adopted by discriminating spine surgeons.”

ALIF IdentiTi-LW Porous Titanium Interbody Implant System

The launch of the IdentiTi Interbody Implant System follows successful alpha evaluations that began in December 2018. It marks the fourth of six IdentiTi implant systems the Company expects to commercially introduce in 2019.

The IdentiTi line of implant systems is manufactured using a subtractive process, which begets more predictable performance, consistent bone-like porosity, and enhanced imaging characteristics. IdentiTi implants not only complement the Company’s current suite of PEEK implants, but also allow ATEC to address the broader market of surgeons who prefer titanium.

“IdentiTi ALIF is one of the first porous titanium ALIF implant solutions to provide a truly unique combination of implant material and geometry,” said Dr. Vedat Deviren, Professor of Orthopaedic Surgery at UCSF Spine Center.  “With a porosity and stiffness similar to bone, combined with a wide range of lordotic implant options, including 20-degree and 30-degree, IdentiTi ALIF is my preferred anterior column interbody device.”

Key Features of the IdentiTi Porous Titanium Interbody Systems

ATEC’s IdentiTi Porous TI Interbody Systems offer implant options that are designed to provide the biological, biomechanical, and imaging characteristics that surgeons seek in a fusion construct. IdentiTi implants take advantage of bone’s affinity for titanium, and because of their porosity, have a surface roughness that enhances stability.

Key features include:

  • Consistent, fully interconnected porosity throughout the implant designed to mimic the structure and porosity of cancellous bone;
  • Proprietary pore structure designed to create surface roughness that enhances immediate implant stability and facilitates surface adhesion;
  • Reduced density (60% porous), which enhances intraoperative and postoperative imaging;
  • Stiffness similar to bone;
  • Subtractive manufacturing process, which creates a consistent porous titanium material that furthers product performance predictability with consistent and reproducible interconnected pore sizes; and
  • Intuitive, low profile, and exacting instruments designed to optimize the surgeon experience and facilitate outstanding patient outcomes.

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc., through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery.  ATEC designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company markets its products in the U.S. via independent sales agents and a direct sales force.

Additional information can be found at www.atecspine.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company’s planned commercial launches, product introductions and product integration, surgeon and market acceptance of Company products, solutions and platforms, and the Company’s ability to deliver key product features. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the Company’s pipeline; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for procedures performed using the Company’s products; the Company’s ability to compete with other products and with emerging new technologies; product liability exposure; patent infringement claims; and claims related to the Company’s intellectual property.  The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company’s most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/883d7bf6-13a2-4936-a967-9f067b020841

Investor/Media Contact:
Tina Jacobsen
Investor Relations 
(760) 494-6790
  
Company Contact:
Jeff Black
Chief Financial Officer
Alphatec Holdings, Inc.
Tags

Chris J. Stewart

Chris currently serves as Chief Operating Officer at Ortho Spine Partners. Prior to that, he was the assistant vice president and business unit leader of Medical Device Management for HealthTrust.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button